Hologic (NASDAQ:HOLX) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Hologic (NASDAQ:HOLX) from a buy rating to a hold rating in a report published on Wednesday.

HOLX has been the subject of a number of other research reports. Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and increased their target price for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Mizuho set a $75.00 target price on Hologic in a research report on Thursday, July 31st. Stephens reissued an “overweight” rating and issued a $78.00 target price on shares of Hologic in a research report on Thursday, September 18th. Finally, Argus increased their target price on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and a consensus price target of $79.38.

Hologic Trading Up 0.5%

HOLX opened at $68.22 on Wednesday. The business has a 50 day simple moving average of $66.97 and a two-hundred day simple moving average of $63.08. The firm has a market capitalization of $15.17 billion, a price-to-earnings ratio of 28.31, a PEG ratio of 2.33 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic has a one year low of $51.90 and a one year high of $84.39.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts predict that Hologic will post 4.28 EPS for the current year.

Insider Buying and Selling at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.88% of the stock is owned by insiders.

Institutional Trading of Hologic

Institutional investors have recently added to or reduced their stakes in the business. Chung Wu Investment Group LLC purchased a new stake in Hologic during the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd boosted its stake in Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 273 shares during the last quarter. Loomis Sayles & Co. L P purchased a new position in shares of Hologic in the 2nd quarter worth $33,000. Zions Bancorporation National Association UT purchased a new position in shares of Hologic in the 1st quarter worth $34,000. Finally, Cromwell Holdings LLC boosted its stake in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 436 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.